Condition: Advanced and Metastatic Solid Tumor · Sponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
This study is one single group of participants with advanced solid tumors. It is the first time the drug has been used in humans. There will be two parts including Dose Escalation and Dose Expansion to evaluate the safety, tolerability, pharmacokinetics, and clinical activity of FZ-AD004.
This description comes directly from the study's public registry record.
Xuejing Cheng · 00-86-021-58953355 · xjcheng@fd-zj.com
Always discuss trial participation with your own doctor first.
| Shanghai Chest Hospital | Shanghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05914545